One thing I took away from reading the full description of Nader and Kazem's douchebaggery, was that the FDA was actually quite responsive and accessible the whole time. I was always under the impression that they were much harder to work with and were possibly slow walking us on top of that. But they were actually quick to respond to things, proactive even, in how they corresponded. It brings me a good deal more hope that with the right people (non criminals and/or idiots) trying to advance Leronlimab to market, the FDA will be not just giving us a fair shake, but that they really are paying attention. They're far more engaged than I would have guessed, and that I'm sure I bitched about at some point on this board. If our current team gives them good data in the way they like to see it, I see no reason they won't afford us timely and appropriate governance.